好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

FcRn Inhibitors in gMG: Leveraging Continuing 好色先生 to Bridge Gaps in Clinical Practice
Neuromuscular and Clinical Neurophysiology (EMG)
P11 - Poster Session 11 (11:45 AM-12:45 PM)
9-011

To improve neurology clinicians’ knowledge, confidence, and behaviors in evaluating generalized myasthenia gravis (gMG) disease severity and integrating targeted treatments such as neonatal Fc receptor (FcRn) inhibitors into clinical decision-making.
Many neurology clinicians face challenges in accurately assessing disease burden and optimizing treatment regimens for patients with gMG. Timely education is critical to ensure they are prepared to incorporate novel FcRn inhibitors into practice.
In February 2025, a live virtual continuing education (CE) webinar was provided, with live faculty moderation and question-and-answer sessions. The enduring version of the webinar will remain available through March 25, 2026. Pre- and post-test assessments were used to quantify the impact of education.
A total of 206 neurology clinicians participated in the education. Clinicians demonstrated limited baseline knowledge across all topics. Regarding assessment, 67% lacked knowledge of tools for gMG assessment and 62% were unfamiliar with the mechanisms of action of FcRn inhibitors. Of note, although 59% of clinicians assessed disease burden before determining treatment options, only 39% evaluated gMG antibody subtype. Baseline awareness of FcRn inhibitors was limited, with only 13% and 25% familiar with clinical evidence of nipocalimab efficacy and rozanolixizumab indication, respectively. These gaps translated into underuse in practice, with 44% of clinicians prescribing complement inhibitors but only 25% reporting experience with FcRn inhibitors. However, post-learning, clinicians were 30% more likely to consider the clinical evidence of FcRn inhibitors when making treatment decisions. Overall knowledge increased by 51%, with 88% of clinicians expressing greater confidence in managing gMG.
This CE initiative revealed critical gaps in gMG management, particularly in disease assessment and familiarity with FcRn inhibitors. 好色先生 significantly improved neurology clinicians’ knowledge and confidence to integrate FcRn inhibitors into treatment decision-making, supporting more informed and personalized patient care.
Authors/Disclosures
Emily Scully (Vindico Medical 好色先生)
PRESENTER 		Emily Scully has nothing to disclose.
Bharati Hegde, PhD Dr. Hegde has nothing to disclose.
Jillian Scavone, PhD Dr. Scavone has nothing to disclose.
Kristin Rose Mrs. Rose has nothing to disclose.
Katie Robinson, PhD (Vindico Medical 好色先生) Dr. Robinson has nothing to disclose.